Combined non-alcoholic fatty liver disease and type 2 diabetes in severely obese patients-medium term effects of sleeve gastrectomy versus Roux-en-Y-gastric bypass on disease markers.
Bariatric surgery
gastric bypass
morbid obesity complications
non-alcoholic fatty liver disease (NAFLD)
sleeve gastrectomy (SG)
transaminases
type 2 diabetes mellitus (T2DM)
Journal
Hepatobiliary surgery and nutrition
ISSN: 2304-3881
Titre abrégé: Hepatobiliary Surg Nutr
Pays: China (Republic : 1949- )
ID NLM: 101600750
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
15
02
2021
accepted:
11
05
2021
entrez:
16
12
2022
pubmed:
17
12
2022
medline:
17
12
2022
Statut:
ppublish
Résumé
We aimed to evaluate the medium-term efficacy of sleeve gastrectomy (SG) We identified severely obese patients [body mass index (BMI) >35 kg/m Ninety-six patients were investigated; 44 (45.8%) were women. The mean pre-operative BMI was 45.2 kg/m Bariatric surgery with SG may be preferable to RYGB for obese patients with NAFLD and T2DM based on the rates of remission of markers of these co-morbidities. However, our results need to be confirmed in prospective trials. Understanding the metabolic effects of specific bariatric surgical procedures may facilitate the development of a personalised approach to weight-loss surgery.
Sections du résumé
Background
UNASSIGNED
We aimed to evaluate the medium-term efficacy of sleeve gastrectomy (SG)
Methods
UNASSIGNED
We identified severely obese patients [body mass index (BMI) >35 kg/m
Results
UNASSIGNED
Ninety-six patients were investigated; 44 (45.8%) were women. The mean pre-operative BMI was 45.2 kg/m
Conclusions
UNASSIGNED
Bariatric surgery with SG may be preferable to RYGB for obese patients with NAFLD and T2DM based on the rates of remission of markers of these co-morbidities. However, our results need to be confirmed in prospective trials. Understanding the metabolic effects of specific bariatric surgical procedures may facilitate the development of a personalised approach to weight-loss surgery.
Identifiants
pubmed: 36523925
doi: 10.21037/hbsn-21-71
pii: hbsn-11-06-795
pmc: PMC9745618
doi:
Types de publication
Journal Article
Langues
eng
Pagination
795-807Informations de copyright
2022 Hepatobiliary Surgery and Nutrition. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-21-71/coif). The authors have no conflicts of interest to declare.
Références
Surg Obes Relat Dis. 2018 Oct;14(10):1607-1616
pubmed: 30146425
Ann Surg. 2015 Mar;261(3):421-9
pubmed: 25405560
Obes Surg. 2018 Dec;28(12):4022-4033
pubmed: 30121855
Diabetes Care. 2009 Nov;32(11):2133-5
pubmed: 19875608
Hepatology. 2011 Aug;54(2):555-61
pubmed: 21567436
Obes Surg. 2018 Mar;28(3):812-819
pubmed: 28965313
Gut. 2020 Aug;69(8):1483-1491
pubmed: 31900291
Clin Gastroenterol Hepatol. 2019 May;17(6):1040-1060.e11
pubmed: 30326299
Lancet Diabetes Endocrinol. 2019 May;7(5):344-355
pubmed: 30852132
Surg Obes Relat Dis. 2021 Jan;17(1):231-238
pubmed: 33036939
Surg Obes Relat Dis. 2016 Jan;12(1):127-31
pubmed: 26077701
Surg Obes Relat Dis. 2019 Feb;15(2):220-226
pubmed: 30598254
Hepatology. 2007 Apr;45(4):846-54
pubmed: 17393509
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Ann Surg. 2021 Jan 1;273(1):66-74
pubmed: 31693504
Br J Surg. 2018 Feb;105(3):168-181
pubmed: 29405276
Obes Surg. 2019 Mar;29(3):1058-1067
pubmed: 30617917
Dig Dis Sci. 2016 May;61(5):1337-47
pubmed: 26848588
Diabetes Care. 2020 Feb;43(2):290-297
pubmed: 31604692
J Hepatol. 2017 Dec;67(6):1265-1273
pubmed: 28803953
Lancet Diabetes Endocrinol. 2014 Feb;2(2):152-64
pubmed: 24622719
Ann Intern Med. 2002 Jul 2;137(1):1-10
pubmed: 12093239
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Obes Surg. 2015 Aug;25(8):1518-26
pubmed: 25982807
Gut. 2014 Aug;63(8):1238-46
pubmed: 24107591
JAMA. 2020 Mar 24;323(12):1175-1183
pubmed: 32207804
N Engl J Med. 2017 Feb 16;376(7):641-651
pubmed: 28199805
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
JAMA Surg. 2018 May 1;153(5):427-434
pubmed: 29214306
Cell Metab. 2020 Feb 4;31(2):233-249.e4
pubmed: 31866441
Obes Surg. 2021 Feb;31(2):564-569
pubmed: 33047289
Lancet. 2011 Aug 27;378(9793):815-25
pubmed: 21872750
Semin Liver Dis. 2014 Feb;34(1):98-107
pubmed: 24782263
Nat Rev Endocrinol. 2012 Sep;8(9):544-56
pubmed: 22525731
Obes Surg. 2016 Oct;26(10):2516-22
pubmed: 27381560
Obes Surg. 2019 Apr;29(4):1295-1300
pubmed: 30635812
Ann Surg. 2017 Nov;266(5):738-745
pubmed: 28767558
Diabetes Obes Metab. 2020 Aug;22(8):1378-1387
pubmed: 32243058
Gastroenterology. 2020 Oct;159(4):1290-1301.e5
pubmed: 32553765
Obes Surg. 2020 Feb;30(2):664-672
pubmed: 31724116
Obes Surg. 2019 Dec;29(12):4066-4076
pubmed: 31655953
Surg Obes Relat Dis. 2015 Nov-Dec;11(6):1315-22
pubmed: 26003897
Endocr Pract. 2015 Apr;21 Suppl 1:1-87
pubmed: 25869408
Surg Obes Relat Dis. 2019 Mar;15(3):502-511
pubmed: 30683512
Obes Surg. 2016 Aug;26(8):1867-74
pubmed: 26660688
Dig Dis. 2015;33(3):440-6
pubmed: 26045281
N Engl J Med. 2017 Sep 21;377(12):1143-1155
pubmed: 28930514
Diabetes Obes Metab. 2021 Apr;23(4):980-990
pubmed: 33368954
Diabetes Obes Metab. 2021 Mar;23(3):742-753
pubmed: 33269505